NTL Healthcare (NTL) announced its participation in the ‘KoINDEX with G-Fair 2024’ (KoINDEX), held in New Delhi, India, from November 21 to 23, 2024, to target the Indian healthcare market of 1.4 billion population. At the event, NTL introduced its cutting-edge AI cervical cancer screening system, Dr. CerviCARE AI®, and the iner:y NKTM (Iner:y NK) feminine cleanser, which contains NK cell culture.



KoINDEX, marking the 50th anniversary of Korea-India diplomatic relations, is the largest exhibition held in India to date. It was also the first Korean-led industrial exhibition in the country, drawing more than 3,600 buyers from India and the South Asian region and concluding successfully.
According to an NTL representative, the company engaged with approximately 100 buyers during the exhibition. Furthermore, they reached specific agreements regarding contracts with central and state government hospitals in India, achieving a meaningful milestone for entering the Indian market.
CerviCARE AI®, an innovative AI-driven cervical cancer screening system, was developed using cervical imaging data accumulated over 28 years of cervical cancer screening services. This system analyzes captured cervical images within just 5 seconds, quickly and accurately distinguishing between normal and abnormal conditions. It is expected to pioneer a new paradigm in women’s cancer prevention.
NTL is a global fem-tech leader, specializing in AI-powered innovations and cutting-edge diagnostic technologies. Dedicated to safeguarding and enhancing women’s health worldwide, the company drives progress in the medical technology industry, shaping the future of women's healthcare.